ArticlePharmaceutics2022

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial.

Juan Espinosa-Pereiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.